---
schema_version: "secwatch.filing_event.v1"
accession: "0001437749-25-007615"
form_type: "8-K"
ticker: "ETON"
cik: "0001710340"
company_name: "Eton Pharmaceuticals, Inc."
filed_at: "2025-03-14T23:59:59+00:00"
generated_at: "2026-05-24T18:38:35.754723+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.72
calibrated_materiality_score: 0.72
confidence: "high"
source: SEC EDGAR
---

# ET-600 passes pivotal bioequivalence study; NDA submission expected April 2025

## Summary
- ET-600 (desmopressin oral solution) met primary endpoint in pivotal bioequivalence study of 75 healthy subjects.
- Company expects to submit NDA to FDA in April 2025; if approved, would be only FDA-approved oral liquid desmopressin.
- CEO Brynjelsen anticipates potential product launch in Q1 2026; pre-launch commercial activities underway.
- ET-600 is a proprietary patented formulation for central diabetes insipidus targeting precise pediatric dosing.

## SEC filing metadata
- accession: 0001437749-25-007615
- form_type: 8-K
- ticker: ETON
- cik: 0001710340
- company_name: Eton Pharmaceuticals, Inc.
- filed_at: 2025-03-14T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.72
- calibrated_materiality_score: 0.72
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1710340/000143774925007615/0001437749-25-007615-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1710340/000143774925007615/eton20250312_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001437749-25-007615
- JSON: https://secwatch.observer/filing/0001437749-25-007615.json
- Plain text: https://secwatch.observer/filing/0001437749-25-007615.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.